An experimental radiotracer known as [¹⁸F]flurpiridaz has met its two primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity in detecting coronary artery disease (CAD), according to the sponsors, GE Healthcare and Lantheus.